Article
Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype.
The journal of allergy and clinical immunology. In practice - 1 Nov 2022
Rabe Klaus F, FitzGerald J Mark, Bateman Eric D, Castro Mario, Pavord Ian D, Maspero Jorge F, Busse William W, Izuhara Kenji, Daizadeh Nadia, Ortiz Benjamin, Pandit-Abid Nami, Rowe Paul J, Deniz Yamo
Abstract excerpt
BACKGROUND: The Global Initiative for Asthma report recommends consideration of add-on biologics for patients with type 2 inflammation (blood eosinophils ≥150 cells/μL, fractional exhaled nitric oxide [Feno] ≥20 parts per billion or allergic asthma) whose asthma cannot be controlled by high-dose inhaled corticosteroids. In QUEST (NCT02414854), add-on dupilumab versus placebo was efficacious in patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.